
FDA grants breakthrough device designation to NeuraMetrix (press release):
“The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation to the NeuraMetrix brain health monitoring solution. The designation is granted for devices “that provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions”. The approved use is monitoring of Parkinson’s disease (PD) [Read more…] about An idea gaining traction: Can measuring typing cadence help monitor and treat Parkinson’s Disease?